tiprankstipranks
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Price & Analysis

2,503 Followers

IOVA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.21 - $18.33
Previous Close$10.88
Volume2.65M
Average Volume (3M)9.16M
Market Cap
$3.04B
Enterprise Value$2.84B
Total Cash (Recent Filing)$279.87M
Total Debt (Recent Filing)$75.86M
Price to Earnings (P/E)-6.0
Beta0.85
Aug 01, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding279,832,722
10 Day Avg. Volume6,563,716
30 Day Avg. Volume9,159,890
Standard Deviation0.27
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.62
Price to Sales (P/S)6316.56
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.39K
Enterprise Value/Gross Profit-296.94
Enterprise Value/Ebitda-14.23
Forecast
Price Target Upside134.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say
Financial AccessibilityWith over 75% of enrolled patients covered by private payors, Amtagvi treatment demonstrates financial accessibility and reimbursement success.
Medical Community EndorsementThe inclusion of Amtagvi as a preferred therapy in the NCCN guidelines for cutaneous melanoma underscores the medical community's support.
Product AdoptionAmtagvi has seen over 100 patients enrolled since its approval, reflecting strong interest and uptake for the treatment.
Bears Say
Drug Safety ConcernsClinical hold for LN-145 in NSCLC after a report of a Grade 5 serious adverse event (patient death).
Financial HealthIovance reports a cash burn of $320-340 million, which is projected to fund operations until the second half of 2025.
Regulatory ChallengesFDA has put a clinical trial on partial hold following the report of a serious adverse event.
---

Financials

Annual

Ownership Overview

12.58%16.15%21.16%50.11%
12.58% Insiders
21.16% Other Institutional Investors
50.11% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

IOVA FAQ

What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $3.21 and its highest was $18.33 in the past 12 months.
    What is Iovance Biotherapeutics Inc’s market cap?
    Currently, no data Available
    When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
    Iovance Biotherapeutics Inc’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
      How were Iovance Biotherapeutics Inc’s earnings last quarter?
      Iovance Biotherapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.424 by $0.004.
        Is Iovance Biotherapeutics Inc overvalued?
        According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Iovance Biotherapeutics Inc pay dividends?
          Iovance Biotherapeutics Inc does not currently pay dividends.
          What is Iovance Biotherapeutics Inc’s EPS estimate?
          Iovance Biotherapeutics Inc’s EPS estimate is -$0.36.
            How many shares outstanding does Iovance Biotherapeutics Inc have?
            Iovance Biotherapeutics Inc has 279,832,730 shares outstanding.
              What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
              Iovance Biotherapeutics Inc reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.424. Following the earnings report the stock price went down -18.513%.
                Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
                Among the largest hedge funds holding Iovance Biotherapeutics Inc’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics Inc’s shares valued at 97M.
                  ---

                  Company Description

                  Iovance Biotherapeutics Inc

                  Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
                  ---

                  IOVA Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  IOVA Stock 12 Month Forecast

                  Average Price Target

                  $25.55
                  ▲(134.83% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","11":"$11","19":"$19","27":"$27","35":"$35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$25.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11,19,27,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.63,15.196923076923078,16.763846153846153,18.33076923076923,19.897692307692306,21.464615384615385,23.03153846153846,24.598461538461535,26.165384615384614,27.732307692307693,29.299230769230768,30.866153846153843,32.43307692307692,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.63,14.546923076923077,15.463846153846156,16.380769230769232,17.29769230769231,18.214615384615385,19.13153846153846,20.048461538461538,20.965384615384615,21.88230769230769,22.799230769230768,23.716153846153848,24.633076923076924,{"y":25.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.63,14.043076923076924,14.456153846153846,14.86923076923077,15.282307692307693,15.695384615384615,16.10846153846154,16.521538461538462,16.934615384615384,17.34769230769231,17.76076923076923,18.173846153846153,18.586923076923078,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.47,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.53,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.63,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Adverum Biotechnologies
                  Kura Oncology
                  Corvus Pharmaceuticals
                  Arcturus Therapeutics

                  Best Analysts Covering IOVA

                  1 Year
                  Peter LawsonBarclays
                  1 Year Success Rate
                  9/16 ratings generated profit
                  56%
                  1 Year Average Return
                  +18.95%
                  reiterated a buy rating 5 days ago
                  Copying Peter Lawson's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +18.95% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis